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ABSTRACT
Background: Palm oil (PO) is used in infant formulas in order to achieve
palmitic acid (PA) levels similar to those in human milk. PA in PO is
esterified predominantly at the SN-1,3 position of triacylglycerol (TAG),
and infant formulas are now available in which a greater proportion of PA is
in the SN-2 position (typical configuration in human milk). As there are
some concerns about the use of PO, we aimed to review literature on health
effects of PO and SN-2-palmitate in infant formulas.
Methods: PubMed and Cochrane Database of Systematic Reviews were
systematically searched for relevant studies on possible beneficial effects or
harms of either PO or SN-2-palmitate in infant formula on various health
outcomes.
Results: We identified 12 relevant studies using PO and 21 studies using SN-2-
palmitate. Published studies have variable methodology, subject characteristics,
and some are underpowered for the key outcomes. PO is associated with harder
stools and SN-2-palmitate use may lead to softer stool consistency. Bone effects
seem to be short-lasting. For some outcomes (infant colic, faecal microbiota,
lipid metabolism), the number of studies is very limited and summary evidence
inconclusive. Growth of infants is not influenced. There are no studies published
on the effect on markers of later diseases.
Conclusions: There is insufficient evidence to suggest that PO should be
avoided as a source of fat in infant formulas for health reasons. Inclusion of
high SN-2-palmitate fat blend in infant formulas may have short-term effects
on stool consistency but cannot be considered essential.
Key Words: colic, constipation, growth, lipids, palm olein, palmitic acid
(JPGN 2019;68: 742–760)
What Is Known
 Palm oil is used as source of fat in infant formula in
order to achieve palmitic acid levels comparable to
human milk.
 Palmitic acid in human milk is predominantly at the
SN-2position, inpalmoil it is predominantly at the SN-
1,3 position. SN-2-palmitate is used in some formulas
to mimick palmitic acid position in human milk.
What Is New
 There is insufficient evidence to suggest that palm oil
should be avoided as a source of fat in infant formulas
for health reasons.
 Inclusion of high SN-2-palmitate fat blend in infant
formulas may have short-term effects on stool con-
sistency but cannot be considered essential.
LIPIDS IN HUMAN MILK AND INFANT
FORMULAS
L ipids in human milk serve as a major source of energy andessential fatty acids (FA) for the breastfed infants. They also
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facilitate absorption of fat-soluble dietary components and support
gastrointestinal function, lipid and lipoprotein metabolism, neuro-
development, and immune function (1,2). Almost 100% of human
milk fat is composed by triacylglycerols (TAG). FA in human milk
are either saturated (SFA, 35%–40%), monounsaturated (MUFA,
45%–50%), or polyunsaturated (PUFA, approximately 15%) (1,2).
Palmitic acid (PA, C16:0) provides the major part of the total SFA
content and its concentration is kept relatively constant in breast-
feeding mothers (2,3). Human milk TAG are predominantly esteri-
fied with PA in the SN-2 position and this configuration facilitates
absorption in infants after digestion by human pancreatic lipase that is
SN-1,3-specific. Nonesterified FA liberated from the SN-1 and SN-3
positions are quite well absorbed if they are unsaturated because of
their water solubility. On the contrary, poorly absorbed saturated FA,
such as PA tend to form calcium (Ca) soaps that are excreted in stool
and increase stool hardness. However, pancreatic lipolysis of human
milk TAG with PA esterified predominantly to the SN-2 position
results in formation of water-soluble palmitoyl-monoglycerol. This
reduces FA and Ca malabsorption and enables the breastfed infant to
benefit from PA as source of fat (see Fig. 1) (1,2,4–10).
The fat in infant formula comes mainly from vegetable oils.
Palm oil (PO) is used in order to achieve PA levels similar to those
in human milk. Recently, there has been an increasing discussion
regarding the use of PO in food products, mostly because of
environmental concerns but PO also has potential important health
effects. In PO, PA is esterified predominantly at the SN-1,3 position
of TAG. As the intestinal absorption of SN-1,3-palmitate is not
optimal, there have been attempts to replace it, at least partly, in
infant formulas with SN-2-predominant TAG (beta-palmitate),
which is the form present in human milk. A number of products
using either a mixture of fat or commercial synthetic beta-palmitate
(eg, Betapol, INFAT, LipoMilk or Zhejiang Beijia product) in order
to achieve high SN-2 content are available on the market. Betapol is
produced by interesterifying a tripalmitin-rich PO fraction with a
mixture of other fats by using the SN-1,3-specific lipase from
Rhizomucor miehei (code SP-392; Novo Industries, Copenhagen,
Denmark). INFAT (Advanced Lipids, Karlshamn, Sweden) is
produced by a patented enzymatic process, which restructures
the fat in a way that mimics the structure of PA in human milk
(SN-2 predominant position).
PALM OIL
PO is the most widely used vegetable oil in the world. It is
obtained from an ancient tropical palm tree (Elaeis guineensis) and
it was one of the major sources of dietary fats for centuries in most
of West Africa (11). Palm kernel oil (PKO) is extracted from the
seeds and edible PO from the mesocarp. PKO has a composition
different from that of PO and is mainly used for nonedible purposes
(4). Compared with most other vegetable oils, PO contains a high
amount of saturated fat (8). Crude palm oil (known also as red palm
oil), contains both compounds beneficial to health (such as TAG,
vitamin E, carotenoids and phytosterols) as well as impurities
(phospholipids, free FA [FFA], gums, and lipid oxidation products).
Both can be removed by refining processes, but the composition of
the final product is dependent on the refining method (chemical or
physical). High-quality PO containing more than 95% neutral TAG,
less than 0.5% FFA and a low impurity content is used in the food
industry. Low-quality oils are used in nonedible industry (6).
PO represents approximately one-third of the world’s vege-
table oil production, and its consumption has increased rapidly in
the past several decades (8). Malaysia and Indonesia are the main
producers of PO, but the E guineensis palm tree is now widespread
throughout the tropical areas of America and South East Asia.
Productivity of PO per unit area is 11, 10, and 7 times the yield of
the other main vegetable oils, soybean, sunflower and rapeseed,
respectively (4). Environmental and economic aspects of PO pro-
duction (such as rainforest destruction, biofuels, and child-labour)
are widely discussed by journalists, consumers, public, and industry
via internet and social media (eg, https://www.theguardian.com/
environment/palm-oil). These aspects are beyond the scope of
this article.
PO has 2 major fractions. Palm olein (POL; 65%–75%) is the
low-melting liquid fraction used mainly in cooking oil for frying
and in margarines. The high-melting solid fraction, palm stearin
(30%–35%), is present in shortenings and hydrogenated oils used
as butter substitutes in some countries. PO is generally found in
baked goods, cereals, confectionary fats, frozen meals, ice cream,
industrial frying fats, margarines, nondairy creamers, salad dres-
sings, supplements/vitamins, and other food products (6).
PO contains 50% SFA, mostly PA (44%) and lower amounts
of stearic acid (5%), 40% MUFA, mostly oleic acid, and 10%
PUFA, mostly linoleic acid. Thus, PA is the principal constituent of
refined PO. FA in PO (as in all vegetable oils) are mainly structured
as TAG having oleic acid predominantly located at the SN-2
position, and PA mainly (over 70%–80%) located at the SN-1
and SN-3 positions. As in human milk, PA is also the main SFA
naturally occurring in animal milk fats, often found at the SN-2
position (beta-position) of TAG—in cow’s milk in approximately
40% and in human milk in 60%–80% (3,5–7).
M.F. conducted a trial using beta-palmitate, which was funded by Industry
(Cow & Gate, now Nutricia; in 1995) and has received honoraria for
attending 2 Consultancy meetings with Enzymotec (a company involved
in the manufacture of beta-palmitate for infant formulas).
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POTENTIAL HEALTH EFFECTS OF PALM OIL
AND PALMITIC ACIDS IN ADULTS
High-fat diets, particularly those rich in SFA, have been
linked to cardiovascular diseases (CVD), obesity, type 2 diabetes
mellitus (T2DM) and cancer. However, studies on potential
unhealthy effects of PO because of the high PA content, are
controversial (6,12,13).
Moreover, PO is cholesterol-free and POL, containing a
substantial amount of oleic acid (48%), was considered by some
authors as a suitable substitute for olive oil in healthy human diets
(6). PO has also been suggested as an alternative for partially
hydrogenated fats in the food supply to reduce transfat intakes
(8). A lower atherogenic power of PO compared with animal fat is
also hypothesized, because of the fact that in PO, PA is usually not
present at the SN-2 position in TAG and it has been shown in animal
experiments that higher percentages of PA at the SN-2 position are
related to the most atherogenic profiles (6).
A meta-analysis of 30 articles including 32 clinical trials
reported that PO significantly increased both low-density lipopro-
tein (LDL) and high-density lipoprotein (HDL) cholesterol when
compared with vegetable oils low in saturated fat, and that PO
increased HDL cholesterol when compared with transfat-containing
oils (8). The authors of a recent review state that there is not enough
evidence to conclude that PO is atherogenic and contributes to
elevated serum cholesterol levels (14). A systematic review and
meta-analysis of 51 dietary intervention trials (many of them
included in the previously mentioned meta-analysis (8) has shown
that both favourable and unfavourable changes in blood lipid-
related markers of CVD occurred when PO replaced the primary
dietary fats (rich in stearic acid, MUFA and PUFA or myristic/lauric
acids), whereas only favourable changes occurred when PO
replaced trans-FA (15). The same author in a previous review
concluded that the evidence on dietary PA or PO and the risk of
cancer is not convincing and specific studies are limited (4). There
is 1 study showing promising data on potential anti-inflammatory
effects of red palm oil and protection against ischemia and reper-
fusion injuries of the heart in an intensive care setting that merits
further investigation (16). Another extensive review reports con-
flicting results regarding all considered outcomes (T2DM, CVD
and cancer) mainly for methodological reasons (6).
There are data from studies on animals and tissue models
showing potential negative health effects of PO compared with PO-
nonsupplemented diet, such as reduced insulin sensitivity and
impaired glucose tolerance, lipotoxicity (negative effect of PA on
mitochondrial function mediated by oxidative stress), inflammation
in adipose tissue and pancreas, and supposed involvement of PA in
regulation of tumour growth (cell proliferation, apoptosis, invasive-
ness) (6). On the contrary, there are number of animal studies showing
potentially beneficial effects of PO on lipid profile (14).
FIGURE 1. Digestion and absorption of triacylglycerol and fatty acids in human intestine. Colipase-dependent pancreatic lipase selectively
hydrolyzes the FA at the SN-1 and 3 positions, yielding FFA and the 2-monoglyceride. Unsaturated FFA and monopalmitin are well absorbable.
Saturated FFA (including PA) are involved in the re-synthesis of new TAG and/or formation of Ca2þ or Mg2þ soaps. FA¼ fatty acids; FFA¼ free fatty
acids; PA¼palmitic acid; Ca¼ calcium.
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OTHER POTENTIALLY BENEFICIAL OR
HARMFUL COMPOUNDS OF PALM OIL
PO is genetic-modification free. Crude PO contains phytoster-
ols, and is the richest natural source of carotenoids (vitamin A
precursors), tocopherols, and tocotrienols (vitamin E compounds)
(6,11,17). The levels of these compounds are affected to various
degrees during processing (personal communication, Specialised
Nutrition Europe [SNE]—an association representing food manufac-
turers, including infant formula producers). The final levels of these
compounds in the PO used in the oil blends for infant and follow-on
formulas depends on the formula manufacturers’ specifications to
meet the nutritional profile of these foods. It is important to note that
the infant and follow-on formulas fatty acid and vitamin profiles are
considered in view of the contribution expected from all ingredients,
not just PO. Tocotrienols are natural inhibitors of cholesterol synthesis
and recent studies point to their potential beneficial biological proper-
ties, such as protection against cancer, cardiovascular diseases, neu-
rodegeneration, oxidative stress, and immune regulation (6,18–20).
On the other hand, PO may contain potentially harmful
substances, such as phospholipids, FFA, gums, and lipid oxidation
products (6). Glycerol-based process contaminants (glycidyl fatty
acid esters [GE], 3-monochloropropanediol [3-MCPD], and 2-
monochloropropanediol [2-MCPD], and their fatty acid esters)
are found in PO, but also in other vegetable oils, margarines,
and some processed foods. The substances form during food
processing, in particular, when refining vegetable oils at high
temperatures (approximately 200 8C). The European Food Safety
Authority (EFSA) points to potential health concerns (genotoxicity,
carcinogenicity) of these compounds especially for young age
groups. In their recent report, EFSA points out the fact that the
intakes of 3-MCPD, especially in exclusively formula-fed infants,
slightly exceeded the stipulated tolerable daily intake of
2mg  kg  day1 (21). Infant formulas that do not contain PO or
POL have relatively low concentrations of 3-MCPD and glycidyl
esters; however, effective industrial mitigation strategies can sub-
stantially lower the content in PO/POL-based formula (22). Infants
consuming solely infant formula may be particularly at risk of
exposure to GE, however, in recent years, because of voluntary
measures taken by producers, levels of GE in PO and fats have
fallen substantially (https://www.efsa.europa.eu/en/press/news/
160503a) (23). Oil blends used in infants and young children
nutrition industry contain levels of contaminants (particularly 3-
MCPD and GE) in line with regulation as low as is technically
possible (SNE, personal communication). Several toolboxes are
available and used by the suppliers to mitigate 3-MCPD esters and
GE in oils (eg, BLL toolbox—see https://www.bll.de/de/lebensmit-
tel/sicherheit/unerwuenschte-stoffe-kontaminanten/3-mcpd-und-
glycidyl-fettsaeureester/toolbox-minimierung-3-mcpd-glycidyl).
The EU has also recently implemented stricter regulations for foods
for infants and young children versus general foods (24).
Some reports show that there may be nonessential trace
elements and radionuclides present in PO, originating from water
and soil on the palm plantations that may affect the health of
consumers. Data are conflicting, the available literature is limited
and further research is needed, however, to confirm or refute this
suspicion (25).
The aim of this position paper is to review evidence for
potential effects of PO and SN-2-palmitate used as source of fat in
infant formula on the health of infants and children. Environmental
effects of PO production will not be addressed in this article.
MATERIALS AND METHODS
We present the results of relevant studies (RCTs and large
observational studies) on possible beneficial or harmful effects of
either PO/POL or SN-2-palmitate (beta-palmitate) as a source of fat
in infant formulas on the following outcomes: composition of stool;
infantile colic; stool frequency and consistency; bone health and
growth; metabolic effects (eg, cardiovascular health, T2DM, hyper-
tension, and lipid profile).
The database Medline (via PubMed) and Cochrane Database
of Systematic Reviews were searched for keywords for publications
up to November 2017—see Appendix 1 (Supplemental Digital
Content, http://links.lww.com/MPG/B600).
RESULTS
In total, we identified 12 relevant studies using PO/POL (5 on
composition of stool, none on infantile colic, 2 on stool frequency
and consistency, 3 on bone health and growth, and 2 on metabolic
effects) and 21 relevant studies using SN-2-palmitate (8 on com-
position of stool, 3 on infantile colic, 3 on stool frequency and
consistency, 5 on bone health and growth, and 2 on metabolic
effects)—see Tables 1 and 2. In the ‘‘Results’’ section, studies are
reported according to their primary outcome. Secondary outcomes
are also mentioned in Tables 1 and 2 and in the ‘‘Discussion’’ part
of the manuscript. The majority of the identified studies are either
industry-supported or performed by employees of formula produ-
cers (also mentioned in Tables 1 and 2). The quality of the studies is
variable; some have methodological problems, such as very low
sample size or the use of multiple interventions (hydrolyzed protein,
oligosaccharides, etc).
Palm Oil/Palm Olein Studies
Composition of Stool (Fatty Acid and Calcium
Content, Intestinal Microbiota)
We identified 5 RCTs on this topic (26–30), 1 of them
composed of 2 subprojects (29) and 2 of them reporting results from
the same cohort of patients (26,30) (see Table 1). All were per-
formed on relatively small numbers of healthy term infants. All
studies consistently reported lower fat and Ca absorption in infants
using PO/POL-based formulas when compared with PO/POL-free
formulas. Only 1 study reported equal fat absorption when soy
protein-based formula was used, irrespective of its PO content (29).
One study also described lower LC-PUFA absorption in POL-based
formula (30). None of the studies reported on intestinal microbiota.
Infantile Colic
No relevant study was identified.
Stool Frequency and Consistency
Both a large observational multicentre study and an unblinded
RCT (composed of 2 subprojects—first on breastfed and the second
on formula-fed infants) have shown less frequent stools and harder
stool consistency in term infants fed/weaned to formula containing
POL when compared with non-POL formula (31,32).
Bone Health and Growth
Three RCTs were identified—all in healthy term infants with
several months of follow-up—focused on bone health and growth
(33–35). Two of the studies reported lower bone mineralization
(measured by dual-energy X-ray absorptiometry [DEXA]) in the
group of infants fed PO/POL-based formula when compared with
PO/POL-free formula (34,35). Two of the studies used partially
hydrolyzed protein-based formula in both intervention and control
arms (33,34). All 3 studies consistently report no difference in
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anthropometric measurements between PO/POL group and PO/
POL-free group.
Metabolic Effects
No relevant intervention studies were found focused primar-
ily on the effect of PO/POL-containing formula on predictors
(markers) of metabolic diseases (cardiovascular health, T2DM,
hypertension, etc) in infants and children. Two RCTs were identi-
fied that focused on lipid profile in healthy infants with several
months of follow-up (36,37). A lower serum TAG level at day 90 in
the non-POL group when compared with the POL-group was found
in the first study but there was no difference in TAG levels when
compared with a human milk group in any of the formula groups
(37). In the other study, infants consuming POL-based follow-up
formula had lower increases in mean serum total cholesterol, LDL,
and apo B by 12 months of age compared with infants ingesting the
standard infant formula or whole cow milk (36).
SN-2-palmitate (Beta-palmitate) Studies
Composition of Stool (Fatty Acid and Calcium
Content, Intestinal Microbiota)
Altogether 8 RCTs were identified on this topic (38–45), 3
of them on preterm infants (39,40,44), the rest on term infants
(see Table 2). The study by Carnielli et al (39) was a subanalysis
of a study previously published by the same group (40). The
studies have consistently shown that a higher SN-2-palmitate
proportion in formula is associated with improved absorption of
Ca and fat, including palmitate. Only 1 study, presented as a
congress abstract only, did not show any reduction in stool total
FA soaps, palmitate soaps, and total FA when increasing SN-2
palmitate in infant formula (42). One study has shown higher
Lactobacillus and Bifidobacteria counts in the stool in high SN-
2-palmitate group when compared with low SN-2-palmitate
group (45).
Infantile Colic
One DB-RCT, 1 single-blinded RCT, and a large uncon-
trolled observational study were identified, all in term infants (46–
48). The DB-RCT tested the effect of SN-2-palmitate alone (46),
whereas the other studies used multiple interventions—partially
hydrolysed SN-2-palmitate formula containing fructo-oligosac-
charides and galacto-oligosaccharides (47,48). All studies have
shown a reduction of crying episodes/frequency of colic, when
SN-2-palmitate formula was used.
Stool Frequency and Consistency
Three DB-RCTs were identified, all in term infants (49–51).
All of the studies used not only SN-2-palmitate, but also prebiotic
oligosaccharides as the intervention, moreover, one of them used
partially hydrolyzed protein formula (49). The first study showed
significantly increased defecation frequency and a trend to softer
stools in the intervention arm, but there was no difference compared
with standard formula (49). The second study did not show any
difference from the control group when only SN-2-palmitate for-
mula was used, however, the stool consistency score was signifi-
cantly lower at day 28 when both SN-2-palmitate and oligofructose-
enriched formula was used (50). In the third study, the SN-2-
palmitate group had significantly softer stools than controls at
week 8. Addition of oligofructose resulted in even fewer formed
stools (51).
Bone Health and Growth
Four RCTs (one of them with unblinded follow-up) in
healthy term infants were identified (52–56). Two of the studies
were focused on bone health and both have shown short-term
positive effects of SN-2-palmitate formula on bone parameters—
bone mineral content (BMC) and mean bone speed of sound (SOS)
at week 12 (54,55), however, unblinded follow-up of 28% of the
original cohort until 10 years of age did not show long-term
persistence of this effect (53). The other 2 studies focused on
anthropometric parameters and did not show any significant differ-
ence at week 12 and/or 135 days of follow-up, respectively,
between SN-2-palmitate and control formulas. The experimental
formula in both studies was enriched also with prebiotic oligosac-
charides, and in one of the studies also contained partially hydro-
lyzed protein, in the other study acidified milk (52,56).
Metabolic Effects
No relevant intervention studies focused primarily on the
effect of SN-2-palmitate formula on predictors (markers) of meta-
bolic diseases (cardiovascular health, T2DM, hypertension, etc) in
infants and children were found. Two studies on healthy term
infants that focused on lipid profile were identified.
The first RCT showed higher (closer to breastfed group)
content of C16:0 FA in the SN-2 position of chylomicron TAG in
infants fed SN-2-palmitate formula when compared with standard
formula (57). In the other study, higher formula SN-2 led to lower n-
9-MUFA, but higher n-6-PUFA and n-3-PUFA in the infant plasma,
higher C18:0 in LDL TAG, and higher apo B and lower apolipo-
protein A-1 (apo A-1) (58).
DISCUSSION
In cow milk and infant formulas, PA predominantly found in
the SN-1 and SN-3 positions is hydrolyzed by pancreatic lipase and
the resulting free PA may form Ca-FA complexes, which are poorly
absorbed—this was previously confirmed by experiments in
rodents and piglets (54,59–65). The overall efficacy of fat absorp-
tion gradually increases both in preterm and term infants postnatally
reflecting the functional development of the gut (66).
Several studies have shown that PO, as the predominant fat
source, or PA present predominantly on SN-1,3 position, may
negatively influence absorption of Ca and FA from infant formulas
(26–30), and SN-2 palmitate positioning has generally an opposite
effect (38,40,41,43–45). One study presented as a congress abstract
did not show any effect of SN-2 palmitate on reduction in stool total
FA soaps, palmitate soaps, and total FA (42). Despite varying
quality of the studies, there is generally convincing evidence of
differences in PA digestion and absorption related to positioning of
PA on the TAG. No clinical conclusions can be directly made from
these findings, but such changes may be relevant to underlying
physiological mechanism for some clinical conditions, such as
infantile colic or constipation and explain the observed effects
on bone health. Moreover, different structure of TAG in infant
formulas may influence intestinal microbiota, but the number of
studies is limited and no clinically relevant conclusions are possible
at the moment (45,51,52,56).
There are 2 RCTs published so far on the effect of high SN2-
palmitate formula on crying episodes in infantile colic (46,48). The
first study did not only evaluate the effect of SN-2-palmitate as the
study formula also contained hydrolyzed protein, a mixture of
galacto- and fructo-oligosaccharides, and had different whey/casein
ratio and carbohydrate content than control formula. Simethicone
was added to standard formula in the control group. Whether the
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clinical effect was because of the PO content is, therefore, unclear
(48). In the second study, the formulas differed only in SN-2-
palmitate content and a reduction in crying was observed. No pre- or
probiotics were used (46). Possible beneficial effects on infant colic
and other minor gastrointestinal problems were described in a large
observational prospective trial; however, the study formula con-
tained fructo- and galacto-oligosaccharides, partially hydrolyzed
proteins and low levels of lactose apart from the SN-2-palmitate,
and there was no control group (47). These findings are promising,
but more data from well-designed RCTs are needed in order to draw
conclusions on the effect of SN-2-palmitate in infant colic. In some
of the studies not primarily focused on colic, minor GI problems
(spit up, vomiting, ‘‘GI intolerance’’) were evaluated as secondary
outcomes (29,31,32,34). No difference was found between inter-
vention and control group in any of the studies. Moreover, mea-
surement of the primary outcome in trials focused on infant colic is
often subject to discussion as it is very difficult to find an objective
measurement for ‘‘crying episodes’’ and researchers have to rely on
subjective evaluation by parents using various questionnaires.
According to a recent consensus paper, limited data suggest that
infant formula with a partial hydrolysate, galacto-oligosaccharides/
fructo-oligosaccharides and added SN-2-palmitate may be of ben-
efit in reducing infantile colic in formula-fed infants in cases where
cow’s milk protein allergy is not suspected (67).
Previously, it was reported that formula-fed infants have
harder stools than breastfed infants. Ca and FA soaps were the
dominant factors significantly related to stool solids and hardness
score across the breastfed and formula-fed groups (68). Vandenplas
and Salvatore (69) in their review on functional gastrointestinal
disorders in infants state that harder stools are frequent in infants fed
formula containing POL or PO as the main source of fat. A large
observational study and a RCT with 2 sub-studies were published on
this topic (having stool frequency or consistency as primary out-
come) suggesting that POL content in infant formulas may be
responsible for this phenomenon (31,32). However, in the observa-
tional study, the 2 formulas differed also in other components (ratio
of other oils, Ca and nucleotides content) (31). Also in the RCTs,
tested and control formulas differed in other aspects (eg, whey:-
casein ratio, content of nucleotides) (32).
A recent meta-analysis of RCTs indicated that infants fed
POL-free formulas had significantly softer stools (difference in
Mean Rank Stool Consistency score 0.355, 95% CI of 0.472 to
0.239, P< 0.001) than infants fed POL-predominant formulas.
However, stool frequencies were similar between both groups
(P¼ 0.6). Studies included in the meta-analysis had many differ-
ences in study design, infant age, formula types, and composition.
The meta-analysis did not include clinical data from infants fed
human milk or SN-2-palmitate (70). Stool frequency and/or con-
sistency was also mentioned as a secondary outcome in other
studies (26,29,33,34). Conclusions from these studies generally
support the hypothesis that PO/POL content in formula may be
associated with harder stools.
Several studies on the effect of SN-2-palmitate on stool
consistency or frequency have been published (49–51). The study
by Bongers et al (49) did not show significant difference in the
effect of SN-2 formula on stool frequency in constipated infants.
However, the authors used 3 different interventions at once (par-
tially hydrolyzed protein, SN2-palmitate, and prebiotics) and the
study was considered to be underpowered for its outcomes (71).
Two studies showed positive effect of SN-2-formula on stool
consistency, which seemed to be enhanced by adding prebiotic
oligofructose (50,51). Stool consistency or frequency is also
reported as one of the outcomes in other studies on Ca/FA balance,
bone health and growth, with conflicting results on the effect of SN-
2-palmitate (40,41,46,47,52). Moreover, softer stools may not
always be perceived positively by mothers. In the study by Kennedy
et al (54), a greater proportion of the mothers using the high SN-2
formula were concerned about runny stools at the age of 3, 6, and 12
weeks. The difference was not seen in the small group of infants
who had started solids by 12 weeks but continued to receive the
study formula. According to a recent consensus paper, a partially
hydrolyzed infant formula with prebiotics and SN-2-palmitate may
be considered as a dietary intervention for functional constipation in
formula-fed infants (67).
For the effect of PO/POL on bone health, the same patho-
physiological background as for stool consistency changes was
suggested (formation of Ca-FA complexes leading to poor Ca
absorption). In an animal model, levels of intestinal calbindin-
D9k (vitamin D-dependent Ca-binding protein) mRNA expression
was higher in piglets fed PO-based formula when compared with
formula with SN-2 predominant synthetic TAG (72). BMC, bone
area (BA), and cortical BA in femur were lower (P¼ 0.002,
P¼ 0.005, and P¼ 0.02, respectively) in piglets fed human milk
fat substitute with a modified TAG structure holding C16:0 pre-
dominantly in the SN-2-position compared with a control (63).
In healthy infants, average BMC and bone mineral density
(BMD) significantly increases during infancy, and body size is the
dominant predictor of bone mineral status (73). Reference values of
body composition obtained by DEXA both in preterm and term
neonates were published (73–75); however there is a large variation
in published normative data for BMC and BMD of both human
milk-fed and formula-fed infants (76).
Jones et al (77) have shown in a longitudinal observational
cohort study (N¼ 330) a positive association between breast-feed-
ing in early life (particularly for 3 months or longer) and bone mass
in 8-year-old children born at term. Schanler et al have shown that
although predominantly formula-fed preterm infants had signifi-
cantly greater BMC values at 16, 25, and 52 weeks, if the predomi-
nantly human-milk fed infants continue to receive human milk,
radius BMC will ‘‘catch-up’’ to that of similar infants given formula
in the posthospitalization period (78). On the contrary, some studies
find that human milk-fed infants have lower bone accretion than do
formula-fed infants (with greater bone accretion when the mineral
content of formula is higher).
Inclusion of PO in infant formula may be responsible for
reduced bone mineral accretion, but other factors play a role, like
maternal nutritional status (vitamin D, Ca) during pregnancy, type
of infant feeding, Ca and phosphorus content of infant formula,
infant vitamin D supplementation, diet, and physical activity during
the toddler and preschool years (79). A small RCT on 67 infants
indicates that during the first 6 months, bone mass accretion is lower
in infants fed human milk or low-mineral (Ca and phosphorus)
formula compared with infants fed moderate-mineral formula.
However, the human milk-fed group had greater bone mass accre-
tion during the second 6 months and by 12 months of age, there were
no differences among the feeding groups (80).
A RCT by Koo et al (35) showing that infants fed PO-based
formula had significantly lower BMC and BMD at 3 and 6 months
than PO-free formula was challenged in 2004 by Clandinin et al (76)
because of lack of inclusion of a human milk control group. Infants
fed human milk have BMC and BMD values well below either of
the 2 study formulas and all are well within published normative
values at both 3 and 6 months of age (the same is valid for the PO-
based formula group after intervention). This questions the clinical
significance of the data, as it is not clear whether bone mineral
accretion higher than that found in breastfed infants is beneficial
(76). Another RCT has shown higher BMC and greater 25-OH
vitamin D serum levels in children fed PO-free formula when
compared with PO formula. However, the PO formula contained
less Ca than the PO-free formula (34). A retrospective study that
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related DEXA performed at 4 years of age (N¼ 178) with type of
infant feeding identified by history has shown no significant
differences in BMC or BMD (P¼ 0.51 and 0.89, respectively)
among children who had exclusively consumed human milk
(n¼ 57), an infant formula containing no PO (n¼ 56) or an infant
formula containing PO (n¼ 65) during the first 4 months of life
(81). This study was criticized because of its methodology (retro-
spective nature not controlling for many potential confounders,
possible variability in measurement, and underpowered sample
size) (82). The authors’ reply to this criticism was that their study
was designed to detect a difference of 0.52 SD of bone mineral
content between feeding groups (82). A systematic review by Koo
et al included 9 publications with non-PO and PO comparison
groups in infants between 28 and 42 weeks of gestational age and up
to 192 days at study onset. The standardized results were consis-
tently significantly (P< 0.05) positive in favour of the feeding with
non-PO formulas with respect to increased intestinal fractional
absorption of fat, PA and Ca and significantly higher BMC. The
authors conclude that avoidance of PO or its substitution with
synthetic TAG in infant formulas can prevent this detrimental
effect (83).
Although a large RCT has shown possible short-term effects
of SN-2-rich formula on bone health in infants (54), in an open-label
extension of part of the original cohort, no significant effect was
shown by DEXA at 10 years of age (53). Thus, it is questionable if
the effect of high-SN-2 is long lasting. Another RCT has shown that
palmitic structural distribution may influence (with borderline
statistical significance) mean bone speed of sound (SOS; a measure
of bone density, microarchitecture, cortical thickness, and elastic-
ity) in term infants (55). In contrast, it has been suggested that SOS
changes during infancy may be independent of the type of early
diet (84).
A meta-analysis by Yu et al (85) (article in Chinese, only
abstract evaluated by authors of this position paper) analyzed the
effect of infant formula containing PA at the SN-2 position, formula
containing PA at the SN-1, 3 positions and formula without PA on
nutrient absorption, BMC, and and stool consistency in infants.
Absorption of fat and Ca was lower, faecal excretion of Ca was
higher, the BMC was reduced, and the incidence of hard stools was
increased when the infant formula provided PA at the SN-1 and SN-
3 positions as compared with formula with PA at the SN-2 positions
or without PA. However, the authors stress that the conclusions
should be used with caution because of the limited quality of
evidence (85).
Published studies that did not include growth as primary
outcome (26,33–38,43–45,51,52,54–57) did not show any signifi-
cant differences between PO/POL/SN-2-palmitate base formulas
and controls. In an animal experiment, a small but significant
improvement in most growth parameters was found in the rats
fed beta-palmitate-based diet when compared with controls (86).
No human intervention studies focused primarily on the
effect of PO/POL/SN-2-containing formula on biomarkers of met-
abolic diseases (cardiovascular health, T2DM, hypertension, etc) as
the primary outcome in infants and children were identified. Scarce
data are available on lipid metabolism both from animal and
human studies.
One study using a piglet model showed that mRNA levels of
hepatic hydroxymethylglutaryl coenzyme A (HMG-CoA) reduc-
tase, and 7alpha-hydroxylase (C7H) are higher (P< 0.05) and
plasma total, HDL, and apo B-containing cholesterol are lower
(P< 0.05) in formula-fed versus milk-fed piglets, irrespective of the
formula TAG source (POL vs synthesized SN-2 predominant
TAG). There was no difference in LDL receptor mRNA levels
(87). This study shows that important components of lipid metabo-
lism are altered by early diet in an animal model, but POL as source
of fat in formula does not seem to play a role. In another study,
plasma lipid percentages of C18:1 and C18:2n-6 were higher in
piglets fed formula with medium chain triglyceride or coconut oil
rather than formulas with C16:0 (from PO or synthesized triglycer-
ide containing predominantly sn-2 C16:0), or sow milk, although
the formulas contained similar C18:1 and C18:2n-6 (88).
In the study by Innis et al, only TAG levels at day 90 were
lower in POL-free formula than in POL formula; however, neither
of the groups had different TAG levels when compared with breast-
fed infants. Moreover, the study was primarily focused on the effect
of n-6 and n-3 FA on growth, visual acuity, and lipid profile in
infants. Thus, no direct conclusions can be made on metabolic
effects of POL by itself (37). The RCT by Fuchs et al has shown that
older infants fed lower fat formula have adequate total energy intake
and normal growth and that the fat composition of the diets
influenced serum lipid and lipoprotein profiles. The design of
the study, however, does not allow any POL-specific conclusions,
and POL as source of dietary fat may not necessarily be fully
responsible for the above-mentioned metabolic changes (36).
Results of an RCT by Nelson and Innis (57) suggest that at least
50% of the dietary SN-2-palmitate is conserved through digestion,
absorption, and chylomicron TAG synthesis in breastfed and for-
mula-fed infants. In another study by Innis et al (58), postprandial
lipoprotein and unesterified FA levels in term infants were different
in children fed SN-2-predominant formula compared with low-SN-
2 formula.
SUMMARY
Despite available data on potential benefits of SN-2-palmi-
tate and potential nonbeneficial effects of PO/POL used in infant
formulas (3,89,90), the current evidence remains inconsistent and
does not allow definite conclusions to be drawn. Published studies
have variable methodology, differ in subject characteristics, and
some of them are underpowered for the key outcomes. Many of the
studies combine different interventions, such as partially hydro-
lyzed protein, prebiotic oligosaccharides, and in some studies
experimental and control formula differ in other aspects-like protein
source and composition, carbohydrates, or mineral content.
Changes in Ca and PA absorption have been reported that may
represent the physiological background for some clinical situations,
such as infantile colic, constipation, or lower BMC and BMD. PO/
POL seem to be associated with harder stools, on the contrary, SN-
2-palmitate use may lead to softer stool consistency. Bone effects
seem to be short-lasting. For some of the outcomes (infant colic,
faecal microbiota, lipid metabolism), the number of studies is very
limited and summary evidence inconclusive. There are no studies
published on the effect of PO/POL/SN-2 in infant formulas and
long-term outcomes/markers of later diseases (CVD, T2DM, obe-
sity, hypertension, cancer, or long-lasting changes in lipid profile).
Growth and infant health-related quality of life seems not to be
influenced irrespective of PO/POL/SN-2 content of the formula
(91). The majority of the studies are supported by (or performed by
employees of) infant formula producers. Moreover, in several
studies, high SN-2 palmitate formula remains inferior to breast
feeding. Thus, because of the lack of high-quality evidence and
inconsistency in the findings of the studies presented here, current
guidelines do not mandate the inclusion of high SN-2 palmitate in
infant formulas (92,93). EFSA successively rejected 2 health claim
petitions for beta-palmitate in 2011 and 2014, respectively
(3,94,95). There are also other potential health benefits of high
dietary SN-2 palmitate suggested in animals, like reduced
gut inflammation in a colitis model and altered tissue endocanna-
binoid concentrations (7,96,97) that warrant further scientific
attention.
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CONCLUSIONS AND RECOMMENDATIONS
On the basis of the available data, the ESPGHAN Committee
on Nutrition:
1. concludes that inclusion of high SN-2-palmitate fat blend in
infant formulas may have short-term effects on stool
consistency because of reduced formation of calcium soaps,
but cannot be considered essential,
2. concludes that there is insufficient evidence to suggest that PO/
POL should be avoided as a source of fat in infant formulas for
health reasons,
3. recommends that all producers of infant formulas takemeasures
to minimize levels of glycerol-based process contaminants in
infant formulas.
The ESPGHAN Committee on Nutrition recommends fur-
ther research on:
1. possible long-term health effects of PO/POL/SN-2-palmitate-
based infant formulas in well-powered RCTs,
2. presence of nonessential trace elements and radionuclides in
PO,
3. potential health benefits of high dietary SN-2 palmitate
suggested in animals, such as reduced gut inflammation in a
colitis model and altered tissue endocannabinoid concentra-
tions,
4. the potential beneficial/harmful effects of other compounds in
PO, like tocotrienols.
DISCLAIMER
ESPGHAN is not responsible for the practices of physicians
and provides guidelines and position papers as indicators of best
practice only. Diagnosis and treatment is at the discretion
of physicians.
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